A comparative study of idarubicin and doxorubicin in a chemically-induced in vivo mouse model for hepatocellular carcinoma
{{output}}
Hepatocellular carcinoma (HCC) remains a major therapeutic challenge with limited systemic treatment options and suboptimal response rates. Anthracyclines such as doxorubicin (DOX) and idarubicin (IDA) are frequently used in clinical settings, including transa... ...
